Clinical trialNCT04485559RecruitingPhase 1Interventional

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

SponsorUniversity of California, San FranciscoEnrollment50High-Grade Glioma (HGG)Low-grade GliomaRecurrent World Health Organization (WHO) Grade II Glioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high-grade gliomas compared to trametinib or everolimus alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Sabine Mueller
University of California, San Francisco
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham, Children'S of Alabama
Birmingham, Alabama, United States
Recruiting
Children'S Hospital Los Angeles
Los Angeles, California, United States
Ashley Margol, MDTom Davidson, MD
Recruiting
University of California, San Diego Rady Children'S Hospital
San Diego, California, United States
Recruiting
University of California, San Francisco
San Francisco, California, United States
Sabine Mueller, MD, PhD, MAS
Recruiting
Children'S National Medical Center
Washington D.C., District of Columbia, United States
Lindsay Kilburn, MDRoger Packer, MD
Recruiting
University of Florida
Gainesville, Florida, United States
Recruiting
Ann & Robert H. Lurie Children'S Hospital of Chicago
Chicago, Illinois, United States
Recruiting
Riley Hospital for Children
Indianapolis, Indiana, United States
Daniel Runco, MD, MSScott Coven, DO, MPH
Recruiting
John Hopkins University
Baltimore, Maryland, United States
Eric Raabe, MD, PhDKenneth Cohen, MD, MBA
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Withdrawn
Children'S Minnesota
Minneapolis, Minnesota, United States
Anne Bendel, MDMaggie Skrypek, MD
Recruiting
Washington University in St. Louis
St Louis, Missouri, United States
Recruiting
Joseph M. Sanzari Children'S Hospital at Hackensack University Medical Center
Hackensack, New Jersey, United States
Recruiting
New York University
New York, New York, United States
Recruiting
Doernbecher Children'S Hospital Oregon Health & Science University
Portland, Oregon, United States
Active, not recruiting
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Cassie Kline, MD, MASJane Mintrum, MD, PhD
Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Everolimus →Trametinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Dec 2020
Primary completion: 31 Dec 2027
Completion: 31 Dec 2027
Last update posted: 18 Aug 2026
Registered enrollment: 50
Registry id: NCT04485559

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.